Novel PET imaging agent targets copper in tumors, detects prostate cancer recurrence early

March 6, 2018, Society of Nuclear Medicine and Molecular Imaging
In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Credit: A Piccardo et al., Galliera Hospital, Genoa, Italy

An Italian study featured in the March issue of the Journal of Nuclear Medicine demonstrates that a novel nuclear medicine imaging agent targeting copper accumulation in tumors can detect prostate cancer recurrence early in patients with biochemical relapse as indicated by rising prostate-specific antigen (PSA) levels.

Copper tends to be more concentrated in tumors, making it a good imaging biomarker. For this study of 50 patients, researchers conducted PET/CT scans comparing the new imaging agent, copper-64 chloride (64CuCl2), with fluorine-18-choline (18F-Choline). Multiparametric (mpMRI) was also conducted. In addition to calculating the detection rate of each imaging modality, the biodistribution, kinetics of the lesions and radiation dosimetry of 64CuCl2 were evaluated.

"This is the first time this novel agent has been compared with 18F-Choline-PET/CT in a considerable number of prostate cancer patients with biochemical relapse," explains Arnoldo Piccardo, of E.O. Ospedali Galliera in Genoa, Italy. He points out, "Early detection of prostate cancer relapse may improve the clinical management of patients, for example implementing early salvage radiotherapy."

The effective dose of 64CuCl2 was determined to be 5.7 mSv, similar to those of other established PET tracers (although higher than for 18F-Choline, which is 4 mSv). Unlike 18F-Choline, 64CuCl2 is neither accumulated in, nor excreted from, the urinary tract (main uptake is in the liver); this allows for thorough pelvic assessment, increasing the possibility of identifying small lesions close to the bladder. No adverse reactions were observed after the injection of 64CuCl2, and results show that 64CuCl2-PET/CT has a higher detection rate than 18F-Choline-PET/CT in patients with low levels of PSA (<1 ng/ml).

"This study determined that the biodistribution of 64CuCl2 is more suitable than that of 18F-Choline for exploring the pelvis and prostatic bed," says Piccardo. "In with biochemical relapse and a low PSA level, 64CuCl2-PET/CT shows a significantly higher detection rate than 18F-Choline-PET/CT." He reports, "Larger trials with this PET tracer are expected to further define its capabilities and role in the management of ."

Explore further: Researchers map prostate cancer relapse using C-11 choline PET and MRI

More information: Arnoldo Piccardo et al, 64CuCl2PET/CT in Prostate Cancer Relapse, Journal of Nuclear Medicine (2017). DOI: 10.2967/jnumed.117.195628

Related Stories

Researchers map prostate cancer relapse using C-11 choline PET and MRI

October 5, 2016
A team of Mayo Clinic researchers has, for the first time, successfully mapped patterns of prostate cancer recurrence, following surgery. Using C-11 choline PET imaging and multiparametric MRI, researchers found an anatomically ...

PSMA PET/CT visualizes prostate cancer recurrence early, impacts radiation therapy

February 1, 2018
A nuclear medicine scan may locate prostate cancer recurrence after radical prostatectomy early after disease recurrence and could help guide salvage radiotherapy, according to new research from the University of California ...

Mayo Clinic gets FDA approval for new imaging agent for recurrent prostate cancer

November 8, 2012
Mayo Clinic has received U.S. Food and Drug Administration approval to produce and administer Choline C 11 Injection, an imaging agent used during a positron emission tomography (PET) scan to help detect sites of recurrent ...

Trio of studies support use of PET/CT scans as prostate cancer staging tool

October 21, 2011
Recent studies have suggested that C-11 choline positron emission tomography/computerized tomography (PET/CT) scans can be utilized as a staging and potentially therapeutic tool in prostate cancer. The results of three studies, ...

First human application of novel PET tracer for prostate cancer

August 7, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the University of Michigan demonstrate the potential of a new PET tracer, Carbon-11 labeled sarcosine (11C-sarcosine), ...

PET/MR effective for imaging recurrent prostate cancer

June 11, 2013
When prostate cancer makes a comeback, it becomes increasingly important to have exceptional imaging available to find all possible regions where cancer has spread to other parts of the body, or metastasized, in order to ...

Recommended for you

10-year follow-up after negative colonoscopies linked to lower colorectal cancer risk

December 17, 2018
Ten years after a negative colonoscopy, Kaiser Permanente members had 46 percent lower risk of being diagnosed with and were 88 percent less likely to die from colorectal cancer compared with those who did not undergo colorectal ...

Survivors of childhood Hodgkin lymphoma face high long-term risk of solid cancers

December 17, 2018
New research refines existing evidence that survivors of childhood Hodgkin lymphoma face an elevated risk of developing various types of solid tumors many years later. In addition, certain subgroups of patients have an especially ...

Treatment shown to improve the odds against bone marrow cancer

December 15, 2018
Hope has emerged for patients with a serious type of bone marrow cancer as new research into a therapeutic drug has revealed improved outcomes and survival rates.

Immunotherapy combo not approved for advanced kidney cancer patients on the NHS

December 14, 2018
People with a certain type of advanced kidney cancer will not be able to have a combination of two immunotherapy drugs on the NHS in England.

New drug seeks receptors in sarcoma cells, attacks tumors in animal trials

December 13, 2018
A new compound that targets a receptor within sarcoma cancer cells shrank tumors and hampered their ability to spread in mice and pigs, a study from researchers at the University of Illinois reports.

Surgery unnecessary for many prostate cancer patients

December 13, 2018
Otherwise healthy men with advanced prostate cancer may benefit greatly from surgery, but many with this diagnosis have no need for it. These conclusions were reached by researchers after following a large group of Scandinavian ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.